Gut and liver · 2026
Sex Differences in Helicobacter pylori Antimicrobial Resistance among 890 Subjects over 20 Years in a Korean Tertiary Hospital.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Choi Yonghoon, Kim Nayoung, Lee Ju Yup, Lee Jung Won, Lee Hae Dong, Lee Jongchan, Jo So Young, Nam Ryoung Hee, Shin Cheol Min
Аннотация
BACKGROUND/AIMS: Although sex-based differences in Helicobacter pylori eradication success rates and antibiotic resistance profiles have been suggested, which are essential for effective eradication of H. pylori, evidence remains limited. The aim of this study was to investigate sex-based differences in antibiotic resistance patterns of H. pylori to better inform eradication strategies.
METHODS: Subjects from whom H. pylori colonies were isolated from gastric mucosal biopsy specimens were consecutively enrolled between 2003 and 2025. Minimum inhibitory concentration tests were performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and moxifloxacin using the agar dilution method.
RESULTS: A total of 890 subjects (510 males and 380 females) were included. Females demonstrated higher resistance rates to clarithromycin (50.0% vs 35.9%; p<0.001), metronidazole (45.3% vs 38.4%; p=0.041), levofloxacin (45.8% vs 33.7%; p<0.001), and moxifloxacin (45.5% vs 34.1%; p=0.001) than males did; however, no significant differences were found for amoxicillin or tetracycline. Stratified analyses revealed significant sex differences in resistance to clarithromycin and levofloxacin among secondary strains (clarithromycin, 80.9% vs. 67.2%, p=0.007; levofloxacin, 61.1% vs. 48.9%, p=0.034), whereas metronidazole resistance among primary strains showed only a marginal sex difference (40.8% vs. 33.2%, p=0.064). Females also demonstrated significantly higher rates of multidrug resistance, and resistance rates progressively increased over time in both sexes.
CONCLUSIONS: Female subjects with H. pylori infection showed higher resistance rates to clarithromycin, metronidazole, fluoroquinolones, and multidrug regimens than males. These findings highlight the importance of considering sex differences when interpreting antimicrobial resistance patterns and selecting eradication strategies. (ClinicalTrials.gov identifier NCT05247112).
METHODS: Subjects from whom H. pylori colonies were isolated from gastric mucosal biopsy specimens were consecutively enrolled between 2003 and 2025. Minimum inhibitory concentration tests were performed for amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, and moxifloxacin using the agar dilution method.
RESULTS: A total of 890 subjects (510 males and 380 females) were included. Females demonstrated higher resistance rates to clarithromycin (50.0% vs 35.9%; p<0.001), metronidazole (45.3% vs 38.4%; p=0.041), levofloxacin (45.8% vs 33.7%; p<0.001), and moxifloxacin (45.5% vs 34.1%; p=0.001) than males did; however, no significant differences were found for amoxicillin or tetracycline. Stratified analyses revealed significant sex differences in resistance to clarithromycin and levofloxacin among secondary strains (clarithromycin, 80.9% vs. 67.2%, p=0.007; levofloxacin, 61.1% vs. 48.9%, p=0.034), whereas metronidazole resistance among primary strains showed only a marginal sex difference (40.8% vs. 33.2%, p=0.064). Females also demonstrated significantly higher rates of multidrug resistance, and resistance rates progressively increased over time in both sexes.
CONCLUSIONS: Female subjects with H. pylori infection showed higher resistance rates to clarithromycin, metronidazole, fluoroquinolones, and multidrug regimens than males. These findings highlight the importance of considering sex differences when interpreting antimicrobial resistance patterns and selecting eradication strategies. (ClinicalTrials.gov identifier NCT05247112).